Galilei Biosciences
Drug development company targeting PARP1, a central regulator of DNA damage repair, glucose and lipid metabolism, to develop therapies for metabolic health and human longevity.
Notes
Galilei Biosciences is a biotechnology company developing therapies that target PARP1 (Poly ADP-ribose polymerase 1), a protein that plays central roles in DNA damage repair, glucose metabolism, and lipid metabolism. The company's approach aims to improve metabolic health and promote healthy longevity.
PARP1 inhibition has been shown in preclinical studies to improve metabolic function and extend healthspan in animal models. Galilei is developing novel small molecules that selectively modulate PARP1 activity to achieve therapeutic benefits without the side effects associated with existing PARP inhibitors used in cancer treatment.
The company is backed by Apollo Health Ventures, a venture capital firm focused on longevity and aging-related biotechnology.
Team
- Leadership team experienced in drug development and longevity research
Additional Research Findings
- Founded circa 2021
- Portfolio company of Apollo Health Ventures
- Target: PARP1 (DNA damage repair, metabolism)
- Focus on metabolic health and longevity
- Novel mechanism distinct from cancer PARP inhibitors
- Headquarters in Boston area
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Apollo Health Ventures | Dusseldorf, Germany / Boston, USA | biotech-focused | seedseries-a+1 | 15 |